Cargando…
Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients
Introduction Venous thromboses and their consequences are among the main causes of death in patients with tumour diseases. The objective of this study is the analysis of risk factors and the evaluation of the applicability of two risk scores in a purely gynaecological oncology patient collective. Th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805188/ https://www.ncbi.nlm.nih.gov/pubmed/31656320 http://dx.doi.org/10.1055/a-0834-6468 |
_version_ | 1783461324712312832 |
---|---|
author | Nezi-Cahn, Sandra Sicking, Isabel Almstedt, Kathrin Battista, Marco Heimes, Anne-Sophie Krajnak, Slavomir Steetskamp, Joscha Hasenburg, Annette Schmidt, Marcus |
author_facet | Nezi-Cahn, Sandra Sicking, Isabel Almstedt, Kathrin Battista, Marco Heimes, Anne-Sophie Krajnak, Slavomir Steetskamp, Joscha Hasenburg, Annette Schmidt, Marcus |
author_sort | Nezi-Cahn, Sandra |
collection | PubMed |
description | Introduction Venous thromboses and their consequences are among the main causes of death in patients with tumour diseases. The objective of this study is the analysis of risk factors and the evaluation of the applicability of two risk scores in a purely gynaecological oncology patient collective. The identification of patients at high risk for the occurrence of venous thromboses could enable the implementation of targeted medication-based thrombosis prophylaxis which has a significant benefit and, simultaneously, a low risk. Materials and Methods A retrospective case-control study on 152 patients who were undergoing oncological treatment in the Department of Gynaecology of the Mainz University Medical Centre between 2006 and 2013 investigated the data from 104 patients with breast, 26 with ovarian and 22 with cervical cancer. A control was assigned to 76 subjects in the case group who suffered a venous thrombosis during chemotherapy and this control coincided in the points of tumour location, age, lymph node involvement, metastasis and time of initial diagnosis. The group differences were analysed using the χ (2) test, t test, Mann-Whitney-U test and a logistic regression analysis. Results There were clear group differences in the lack of inpatient thrombosis prophylaxis (p = 0.014), elevated leukocyte counts (p = 0.018) prior to the start of chemotherapy and port systems (p = 0.032). Surgical interventions were confirmed to be an independent risk factor (p ≤ 0.001). The Khorana and Protecht scores did not emerge from the analysis as independent predictors for a thrombosis. More patients died in the case group than in the control group (p = 0.028; OR: 8.1; CI: 1.254 – 52.162). Conclusion In this patient collective, surgeries represent an independent risk factor for venous thromboses. In addition, a correlation was seen between inpatient thrombosis prophylaxis, leukocytosis as well as port systems and an increased risk of thrombosis. Neither the Khorana nor the Protecht score were independent risk factors for venous thromboses. Significantly more thrombosis patients died during the observation period. |
format | Online Article Text |
id | pubmed-6805188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-68051882019-10-24 Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients Nezi-Cahn, Sandra Sicking, Isabel Almstedt, Kathrin Battista, Marco Heimes, Anne-Sophie Krajnak, Slavomir Steetskamp, Joscha Hasenburg, Annette Schmidt, Marcus Geburtshilfe Frauenheilkd Introduction Venous thromboses and their consequences are among the main causes of death in patients with tumour diseases. The objective of this study is the analysis of risk factors and the evaluation of the applicability of two risk scores in a purely gynaecological oncology patient collective. The identification of patients at high risk for the occurrence of venous thromboses could enable the implementation of targeted medication-based thrombosis prophylaxis which has a significant benefit and, simultaneously, a low risk. Materials and Methods A retrospective case-control study on 152 patients who were undergoing oncological treatment in the Department of Gynaecology of the Mainz University Medical Centre between 2006 and 2013 investigated the data from 104 patients with breast, 26 with ovarian and 22 with cervical cancer. A control was assigned to 76 subjects in the case group who suffered a venous thrombosis during chemotherapy and this control coincided in the points of tumour location, age, lymph node involvement, metastasis and time of initial diagnosis. The group differences were analysed using the χ (2) test, t test, Mann-Whitney-U test and a logistic regression analysis. Results There were clear group differences in the lack of inpatient thrombosis prophylaxis (p = 0.014), elevated leukocyte counts (p = 0.018) prior to the start of chemotherapy and port systems (p = 0.032). Surgical interventions were confirmed to be an independent risk factor (p ≤ 0.001). The Khorana and Protecht scores did not emerge from the analysis as independent predictors for a thrombosis. More patients died in the case group than in the control group (p = 0.028; OR: 8.1; CI: 1.254 – 52.162). Conclusion In this patient collective, surgeries represent an independent risk factor for venous thromboses. In addition, a correlation was seen between inpatient thrombosis prophylaxis, leukocytosis as well as port systems and an increased risk of thrombosis. Neither the Khorana nor the Protecht score were independent risk factors for venous thromboses. Significantly more thrombosis patients died during the observation period. Georg Thieme Verlag KG 2019-10 2019-06-05 /pmc/articles/PMC6805188/ /pubmed/31656320 http://dx.doi.org/10.1055/a-0834-6468 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Nezi-Cahn, Sandra Sicking, Isabel Almstedt, Kathrin Battista, Marco Heimes, Anne-Sophie Krajnak, Slavomir Steetskamp, Joscha Hasenburg, Annette Schmidt, Marcus Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients |
title | Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients |
title_full | Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients |
title_fullStr | Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients |
title_full_unstemmed | Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients |
title_short | Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients |
title_sort | risk factors for chemotherapy-associated venous thromboses in gynaecological oncology patients |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805188/ https://www.ncbi.nlm.nih.gov/pubmed/31656320 http://dx.doi.org/10.1055/a-0834-6468 |
work_keys_str_mv | AT nezicahnsandra riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients AT sickingisabel riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients AT almstedtkathrin riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients AT battistamarco riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients AT heimesannesophie riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients AT krajnakslavomir riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients AT steetskampjoscha riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients AT hasenburgannette riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients AT schmidtmarcus riskfactorsforchemotherapyassociatedvenousthrombosesingynaecologicaloncologypatients |